As of June 2026, more than a dozen lawsuits alleging that Sanofi’s “domestic blockbuster” eczema drug Dupixent (dupilumab) had dangerous and even deadly side-effects, including cutaneous T-cell lymphoma (CTCL), have been consolidated in federal court in New Jersey. Lieff Cabraser and other law firms are pursuing damages claims in the litigation in connection with its development, testing, labeling, packaging, promoting, advertising, marketing, distribution, and sale.
A biologic medication injected for the treatment of multiple conditions, including atopic dermatitis (ecxema), asthma, nasal polyps, and other inflammatory diseases of the skin and respiratory tract in adult and child patients, the pending lawsuits allege that Dupixent caused the development and/or aggravation of T-cell lymphoma (CTCL) in some patients. (T-cell lymphoma is a rare type of cancer that affects white blood cells called T cells, or T lymphocytes.).
Numerous case reports and scientific studies have established a link between Dupixent and T-cell lymphoma, including CTCL and PTCL (Peripheral T-Cell Lymphoma) including providing evidence that it causes and/or accelerates progression of the lymphoma. As the filed lawsuits detail, defendants allegedly failed to warn, instruct, advise, educate, or otherwise inform Dupixent users and prescribers about the risk of development and/or exacerbation of CTCL and PTCL.
What Consolidation Means for Injured Dupixent Users
The decision to consolidate the cases will enhance litigation efficiencies and ensure consistent case outcomes for injured Dupixent users. If you or a family member suffered from CTCL or PTCL during or after Dupixent use, you might have a claim for damages. We recommend that you reach out today to a drug defect lawyer at Lieff Cabraser or another firm. Please call us directly at 800 541-7358 or use the secure contact form on this page.
We welcome the opportunity to discuss your case and legal options, and to provide information on your rights and potential recovery.
Nationally-Recognized Prescription Drug Injury Attorneys
The plaintiff-side-only law firm Lieff Cabraser Heimann & Bernstein has litigated and resolved thousands of individual lawsuits and class and group actions, including some of the most important prescription drug injury cases in the United States over the past five decades, including in the national opioid fraud and addiction litigation. We have assisted our clients in recovering over $133 billion in verdicts and settlements, and have been repeatedly named product liability (including drug injury) practice group of the year by publications including Law360, the National Law Journal, The California Daily Journal, the New York Law Journal, Best Lawyers, Benchmark, Legal500, and Chambers & Partners USA.
Learn more about the Dupixent Prescription Drug Injury Litigation.
Contact us
Use the form below to contact a lawyer at Lieff Cabraser. Please note that our firm does not provide services in the areas of criminal defense, individual landlord-tenant matters, or housing accommodations, and will not respond to inquiries in those areas.
